JPRN-UMIN000016870
Completed
未知
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization - Intravitreal tPA and ranibizumab for type 2 choroidal neovascularization
agoya City University Graduate School of Medicine0 sites20 target enrollmentMarch 23, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Subfoveal type 2 choroidal neovascularization
- Sponsor
- agoya City University Graduate School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •eyes with previous photodynamic therapy, medication for glaucoma, diabetic retinopathy, epiretinal membrane, vitreomacular traction, or high myopia (\-6\.0 diopters or worse)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
Recruiting
Not Applicable
vitreous surgery with intravitreal tissue plasminogen activator(t-PA)globe ruptureJPRN-UMIN000015282Okayama University Hospital30
Not yet recruiting
Not Applicable
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Corticosteroid for Macular EdemaKCT0007766Hallym University Medical Center-Kangnam188
Completed
Not Applicable
Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000013975agoya University hospital ophtalmoligy30
Active, not recruiting
Phase 2
sing panitumumab with ranibizumab injected into the eye to treat exudative age-related macular degeneratioExudative age-related macular degenerationEye DiseasesISRCTN85022211fa Eye Research Institute200